e-learning
resources
Virtual 2020
Pre-Congress Content
Prognosis and biomarkers of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker?
. d'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Cameli (Siena, Italy), A. Carleo (Hannover, Germany), P. Sestini (Siena, Italy), E. Bargagli (Siena, Italy)
Source:
Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Session:
Prognosis and biomarkers of idiopathic pulmonary fibrosis
Session type:
E-poster session
Number:
823
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
. d'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Cameli (Siena, Italy), A. Carleo (Hannover, Germany), P. Sestini (Siena, Italy), E. Bargagli (Siena, Italy). Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker?. 823
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Defining the role of neutrophil-to-lymphocyte ratio in COPD patients
Source: Virtual Congress 2020 – Prognosis and integrated management of COPD
Year: 2020
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?
Source: International Congress 2017 – Rare diseases
Year: 2017
The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients.
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Is FEV1/FEV6 ratio a reliable tool in COPD diagnosis ?
Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations
Year: 2021
Mortality risk prediction in COPD by a prognostic biomarker panel
Source: Eur Respir J 2014; 44: 1557-1570
Year: 2014
Is YKL-40 a prognostic marker in sarcoidosis?
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Is neutrophil/lymphocyte ratio at the time of diagnosis a valuable prognostic factor in non-small cell lung cancer?
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
Clinical phenotyping of COPD patients: a simple tool with prognosis value
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018
Malignant mesothelioma, are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio prognostic indicator parameters as reliable?
Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors
Year: 2015
Prognostic value of neutrophil-to-lymphocyte ratio in hospitalized patients with COVID-19
Source: Virtual Congress 2021 – COVID - 19
Year: 2021
The prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with non-small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
Lipocalin-2: a biomarker potentially associated with predisposition to COPD
Source: Virtual Congress 2020 – Cellular stress in respiratory diseases
Year: 2020
Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho
Source: Eur Respir J 2014; 43: 322-324
Year: 2013
Is it useful CD4+CD103+/CD4+ ratio for the diagnosis of lung sarcoidosis?
Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases
Year: 2011
Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD
Source: Eur Respir J 2014; 43: 951-953
Year: 2014
The new prognostic multidimensional index HODEH in patient with COPD
Source: Annual Congress 2008 - Prognosis in COPD
Year: 2008
Prognostic value of haematological markers such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in small cell lung cancer.
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Can YKL-40 be used as a biomarker and therapeutic target for adult asthma?
Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017
Year: 2018
C-reactive protein/albumin ratio as a prognostic biomarker in critically ill septic patients: a prospective study
Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine
Year: 2020
Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept